Digestive Health Newsletter

Good Nutrition for a Bad Gut: Focus on Iron

Gina Storrs, RN, CNP

Volume 20, 
April 01, 2010

by Gina Storrs, RN, CNP

Gina Storrs Gina Storrs, RN, CNP, has practiced nursing for more than 28 years. She has worked with patients with inflammatory bowel disease for the last 11 years in a large, private practice gastroenterology office in the Minneapolis-St. Paul area. She has lectured regionally and nationally on many different gastroenterology topics, including inflammatory bowel disease, irritable bowel syndrome, and liver disease. She is board certified by the American Nurses Credentialing Center, and is a member of the American Gastroenterological Association, the Crohn’s and Colitis Foundation, and the American Association for the Study of Liver Diseases.



Table of Contents



Introduction

Good nutrition is always important, but it is especially important when you have inflammatory bowel disease (IBD). Maintaining adequate nutrition is one of the ways that your body can restore itself to health. This can be a challenge when your IBD symptoms affect both your appetite and your ability to absorb nutrients from the food you eat. This newsletter will focus on iron, which is one of the most common nutrient deficiencies seen in people with IBD.

Back to Top

Why is iron important?

Iron is an important part of hemoglobin, which is the part of the red blood cell that supplies your body with oxygen. Too little iron can result in iron deficiency, which in turn can lead to iron deficiency anemia. Iron deficiency anemia means that your hemoglobin level is lower than normal due to a lack of enough iron. About 45% of people with IBD are iron deficient, and at least 18% of people with IBD have anemia, with some estimates as high as 42%.

Back to Top

Why are people with IBD at increased risk of iron deficiency?

There are several reasons why you may be at increased risk for iron deficiency if you have IBD. You may find that iron-rich foods are difficult to tolerate or are no longer palatable. Your body may also have difficulty absorbing iron from foods, due to the inflammation and diarrhea that can accompany IBD. Finally, you may experience iron loss due to chronic intestinal bleeding.

Back to Top

What are the symptoms of iron deficiency?

Symptoms of iron deficiency can include fatigue, pale skin, hair loss, irritability, weakness, and brittle or grooved nails.

Back to Top

How are anemia and iron deficiency diagnosed?

Anemia can be diagnosed using a simple blood test to check your hemoglobin level. A hemoglobin level below 13.0 g/dL in men or below 12.0 g/dL in women with IBD typically indicates the presence of iron deficiency anemia, which can then be further categorized as mild, moderate, or severe. If you are have a low hemoglobin level, you will likely need more tests to determine the cause of the anemia and the most appropriate treatment. Keep in mind that not all anemia is caused by iron deficiency - there may be other reasons for low hemoglobin.

Back to Top

What can I eat to help prevent and treat iron deficiency?

The general recommended dietary allowance of iron is 18 mg per day. General dietary guidelines are based on a normal sized adult person without significant health issues. Recommended dietary allowances of many nutrients may be different for people with illnesses like IBD and can also vary between males and females.

Beef and meat from other animals are the best sources of dietary iron, in terms of iron content and ease of absorption. A good rule of thumb is that the darker the meat, the higher the iron content. For example, a serving of beef liver provides more iron than a serving of ground beef (7.5 mg. vs. 3.9 mg.), and a serving of pork chop provides more iron than a serving of chicken breast (3.5 mg. vs. 0.9 mg.). Other good sources of iron include egg yolks; prunes and prune juice; other dried fruits (e.g., raisins, apricots, and peaches); beans and nuts; iron-fortified bread, cereal, or pasta; and dark, leafy green vegetables. You can check a food’s Nutrition Facts label to see how much iron you will get in one serving. Look for foods that provide at least 20% of the daily value (DV) for iron.

Back to Top

Are there other ways I can boost my iron intake?

In addition to eating iron-rich foods, there are other things you can do to get more iron in your diet. For example, foods that are rich in vitamin C (citrus fruits and juices, strawberries, and tomatoes) enhance iron absorption from non-meat sources of iron, so try eating both in the same meal. Conversely, foods that are high in calcium or fiber can make it more difficult for your body to absorb iron. This doesn’t mean that you have to give up calcium- and fiber-rich foods, just be sure to eat them as part of meals that do not also contain iron-rich foods. Also try limiting coffee, tea, and soda, all of which interfere with iron absorption. Finally, if you use cast iron pots and pans, the food you cook will absorb iron from your cookware. This works best with acidic foods, like tomatoes and tomato-based sauces.

Back to Top

What about iron supplements?

Iron supplementation can be a way to increase your iron intake if you are not getting enough from the foods you eat. Iron supplements typically come in tablet form, although if you have severe iron deficiency anemia or serious side effects with oral iron supplements, intravenous (IV) iron replacement may be necessary.

The best oral iron supplements contain ferrous sulfate, ferrous gluconate, or ferrous fumerate, so check for those on the ingredient label. If you find that iron supplements upset your stomach or cause constipation, try taking a slow-release form (look for “slow Fe” or “slow iron” on the label). Dark stools can be another side effect when taking iron supplements. If you are also taking a calcium supplement, be sure to do so at a different time of day, since calcium can interfere with iron absorption.

Always be sure to check with your health care provider before taking any new medication or supplement. Unlike many other supplements, iron overdose is very dangerous. Never take a double dose to make up for a missed dose, and keep your supplements out of easy reach. As few as three adult iron tablets can be fatal to a child.

Back to Top

Conclusion

Even though iron deficiency can be a common complication of IBD, it is easily treatable. The appropriate treatment can have a significant impact on your quality of life. In fact, research has shown that treating iron deficiency anemia may improve the course of IBD. Keep in mind that anemia can gradually progress over a long period of time and may not be noticeable until it is relatively severe, so be sure to talk to your health care provider if you think you are at risk.

Back to Top

Important Safety Information about AZASAN

WARNING: Chronic immunosuppression with this purine antimetabolite increases risk of neoplasia in humans. Physicians using this drug should be very familiar with this risk as well as with the mutagenic potential to both men and women and with possible hematologic toxicities. See WARNINGS section in complete Prescribing Information.

AZASAN® (azathioprine tablets) 75/100 mg is indicated as an adjunct for the prevention of rejection in renal homotransplantations, and also for the management of active rheumatoid arthritis to reduce signs and symptoms.The most commonly reported side effects associated with AZASAN therapy are leukopenia and/or thrombocytopenia, secondary infections, neoplasia, nausea, vomiting, diarrhea, fever, myalgias, skin rashes, and hepatotoxicity. AZASAN therapy should be given cautiously when used concomitantly with allopurinol, ACE inhibitors, and other agents affecting myelopoiesis. AZASAN is contraindicated in pregnant and lactating women and in patients who have shown hypersensitivity to this product.

Consult with your physician to see if this product is right for you.

Complete Prescribing Information for AZASAN, including BOXED WARNINGpdf

Important Safety Information about METOZOLV® ODT

WARNING: TARDIVE DYSKINESIA

See full prescribing information for complete boxed warning.

Treatment with metoclopramide can cause tardive dyskinesia, a serious movement disorder that is often irreversible. The risk of developing tardive dyskinesia increases with the duration of treatment and the total cumulative dose.

Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia. There is no known treatment for tardive dyskinesia. In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.

Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing tardive dyskinesia.

METOZOLV® ODT (metoclopramide HCl) is indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux disease (GERD) who fail to respond to conventional therapy and for the relief of symptoms associated with acute and recurrent diabetic gastroparesis (diabetic gastric stasis) in adults. Therapy should not exceed 12 weeks in duration. Take on an empty stomach up to four times daily, at least 30 minutes before eating and at bedtime.

METOZOLV ODT is contraindicated in patients with intestinal obstruction, hemorrhage, or perforation; pheochromocytoma; known sensitivity or intolerance to metoclopramide; epilepsy; or are receiving concomitant medications with extrapyramidal reactions.

Extrapyramidal symptoms (EPS), manifested primarily as acute dystonic reactions, occur in approximately 1 in 500 patients treated with the usual adult dosages of 30 to 40 mg/day of metoclopramide. These usually are seen during the first 24 to 48 hours of treatment with metoclopramide, occur more frequently in pediatric patients and adult patients less than 30 years of age and are even more frequent at higher doses.

Drug-induced Parkinsonism can occur during metoclopramide therapy, more commonly within the first 6 months after beginning treatment, but also after longer periods. Patients with a history of Parkinson’s disease should be given metoclopramide cautiously, if at all, since such patients can experience exacerbation of Parkinsonian symptoms when taking metoclopramide.

There have been rare reports of an uncommon but potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) associated with metoclopramide. Clinical manifestations of NMS include hyperthermia, muscle rigidity, altered consciousness, and evidence of autonomic instability. The management of NMS should include immediate discontinuation of metoclopramide and other drugs not essential to concurrent therapy.

Depression associated with metoclopramide use has occurred in patients with and without a history of depression. For those patients with a prior history of depression, metoclopramide should only be given if the expected benefits outweigh the potential risks.

In one study in hypertensive patients, intravenously administered metoclopramide was shown to release catecholamines; hence, caution should be exercised when metoclopramide is used in patients with hypertension. Any rapid rise in blood pressure associated with METOZOLV ODT use should result in immediate cessation of metoclopramide use in those patients.

Since metoclopramide produces a transient increase in plasma aldosterone, patients with cirrhosis or congestive heart failure may be at risk of developing fluid retention and volume overload. If these side effects occur at any time in any patients during metoclopramide therapy, the drug should be discontinued.

Adverse reactions, especially those involving the nervous system, may occur after stopping the use of METOZOLV ODT.

In clinical studies, the most frequently reported adverse events (≥2% occurrence) were headache, nausea, fatigue, somnolence, and vomiting.

Complete Prescribing Information for METOZOLV ODT, including BOXED WARNING pdf

Important Safety Information about OSMOPREP

WARNINGS

There have been rare, but serious reports of acute phosphate nephropathy in patients who received oral sodium phosphate products for colon cleansing prior to colonoscopy. Some cases have resulted in permanent impairment of renal function and some patients required long–term dialysis. While some cases have occurred in patients without identifiable risk factors, patients at increased risk of acute phosphate nephropathy may include those with increased age, hypovolemia, increased bowel transit time (such as bowel obstruction), active colitis, or baseline kidney disease, and those using medicines that affect renal perfusion or function (such as diuretics, angiotensin converting enzyme [ACE] inhibitors, angiotensin receptor blockers [ARBs], and possibly nonsteroidal anti–inflammatory drugs [NSAIDs]).

It is important to use the dose and dosing regimen as recommended (PM/AM split dose).

OSMOPREP® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP) Tablets are indicated for cleansing of the colon as a preparation for colonoscopy in adults 18 years of age or older. Considerable caution should be advised before OSMOPREP is used in patients with severe renal insufficiency, congestive heart failure, ascites, unstable angina, gastric retention, ileus, severe chronic constipation, bowel perforation, toxic megacolon, gastric bypass or stapling surgery, or hypomotility syndrome. Use with caution in patients with impaired renal function, patients with a history of seizures or at higher risk of seizure, patients with higher risk of cardiac arrhythmias, known or suspected electrolyte disturbances (such as dehydration), or people taking drugs that affect electrolyte levels. Patients with electrolyte abnormalities such as hypernatremia, hyperphosphatemia, hypokalemia, or hypocalcemia should have their electrolytes corrected before treatment with OSMOPREP.

OSMOPREP is contraindicated in patients with a known allergy or hypersensitivity to sodium phosphate salts or any of its ingredients, and in patients with biopsy–proven acute phosphate nephropathy. In clinical trials, the most commonly reported adverse reactions (reporting frequency >3%) were abdominal bloating, nausea, abdominal pain, and vomiting. It is recommended that patients receiving OSMOPREP be advised to adequately hydrate before, during, and after the use of OsmoPrep.

For complete Prescribing Information for OSMOPREP including BOXED WARNING.pdf

Important Safety Information about VISICOL

WARNINGS

There have been rare, but serious reports of acute phosphate nephropathy in patients who received oral sodium phosphate products for colon cleansing prior to colonoscopy. Some cases have resulted in permanent impairment of renal function and some patients required long-term dialysis. While some cases have occurred in patients without identifiable risk factors, patients at increased risk of acute phosphate nephropathy may include those with increased age, hypovolemia, increased bowel transit time (such as bowel obstruction), active colitis, or baseline kidney disease, and those using medicines that affect renal perfusion or function (such as diuretics, angiotensin converting enzyme [ACE] inhibitors, angiotensin receptor blockers [ARBs], and possibly nonsteroidal anti-inflammatory drugs [NSAIDs]).

It is important to use the dose and dosing regimen as recommended (PM/AM split dose).

VISICOL® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP) Tablets are indicated for cleansing of the colon as a preparation for colonoscopy in adults 18 years of age or older. VISICOL is not to be used in patients with congestive heart failure, ascites, unstable angina pectoris, gastric retention, ileus or acute obstruction or pseudo-obstruction, severe chronic constipation, bowel perforation, acute colitis, toxic megacolon, or hypomotility syndrome. Use with caution in patients with impaired renal function, pre-existing electrolyte disturbances, or people taking drugs that affect electrolyte levels. VISICOL is contraindicated in patients with a known allergy or hypersensitivity to sodium phosphate salts or any of its ingredients. In clinical trials, the most commonly observed (≥1%) adverse reactions occurring with use of VISICOL were generally transient and self-limited and included nausea, vomiting, abdominal bloating, abdominal pain, dizziness and headache.

Consult with your physician to see if this product is right for you.

Complete Prescribing Information for VISICOL, including BOXED WARNING pdf

The information contained on this page is intended for US patients, healthcare professionals, and pharmacists only.

Salix Pharmaceuticals on Facebook   Salix Pharmaceuticals on Twitter